Safran : The medium term resistance level limits the upside potential
Entry price | Target | Stop-loss | Potential |
---|
€124.48 |
€116.08 |
€127.78 |
+6.75% |
---|
Safran shares trade close to a major resistance zone that is situated around 115.25 EUR. This zone should be difficult to break through, which in turn suggests a corrective move ahead.
StrengthsWeaknesses● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.63 times its estimated earnings per share for the ongoing year.
●
●
● The company is not the most generous with respect to shareholders' compensation.
● For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
● Revenue estimates are regularly revised downwards for the current and coming years.
● For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.